Author

Jinsong Tao

University of MichiganORCID 0000-0001-5978-0791Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Bo WeniD· 2 shared Chengyi LiiD· 2 shared Duxin SuniD· 2 shared Hanning Wen· 2 shared Hongyi ZhaoiD· 2 shared Miao He· 2 shared Fang KeiD· 1 shared Mahamadou Djibo· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Bo WenORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintSep 2, 2025

Albumin-STING Nanoagonist Reprograms HSPCs to Antitumor Neutrophils Enhancing MHC I-Mediated CD8+ T Cell Immunity

Jinsong Tao, Hongyi Zhao, Chengyi Li…·Duxin Sun

This paper shows that an albumin-STING nanoagonist reprograms hematopoietic stem/progenitor cells into antitumor neutrophils, enhancing CD8+ T cell immunity against tumors.

DOI 10.1101/2025.09.02.673154

mouseexperimental assay

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintFeb 14, 2024

Dual Targeting of STING and PI3Kγ Eliminates Regulatory B Cells to Overcome STING Resistance for Pancreatic Cancer Immunotherapy

Chengyi Li, Shuai Mao, Hongyi Zhao…·Duxin Sun

This paper develops a dual-targeting compound that eliminates regulatory B cells and overcomes STING resistance in pancreatic cancer, improving immunotherapy outcomes.

DOI 10.1101/2024.02.14.580378

mouseproteomics

𝕏 PostBluesky